Pembrolizumab plus chemotherapy versus pembrolizumab monotherapy for PD-L1-positive advanced non-small cell lung cancer in the real world

被引：0

作者：

Sugisaka, J. ^{[1
]}

Sugawara, S. ^{[1
]}

Toi, Y. ^{[1
]}

Ogasawara, T. ^{[1
]}

Aso, M. ^{[1
]}

Tsurumi, K. ^{[1
]}

Ono, K. ^{[1
]}

Shimizu, H. ^{[1
]}

Domeki, Y. ^{[1
]}

Aiba, T. ^{[1
]}

Kawana, S. ^{[1
]}

Saito, R. ^{[1
]}

Terayama, K. ^{[1
]}

Kawashima, Y. ^{[1
]}

Nakamura, A. ^{[1
]}

Yamanda, S. ^{[1
]}

Kimura, Y. ^{[1
]}

Honda, Y. ^{[1
]}

机构：

[1] Sendai Kousei Hosp, Dept Pulm Med, Sendai, Miyagi, Japan

来源：

ANNALS OF ONCOLOGY | 2019年 / 30卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

336P

引用

页数：2

共 50 条

[21] Real-world treatment patterns and outcomes in PD-L1-positive non-small cell lung cancer
Zhang, Xinke
DeClue, Richard W.
Herms, Lisa
Yang, Mo
Pawar, Vivek
Masters, Elizabeth T.
Ruisi, Mary
Chin, Kevin
Velcheti, Vamsidhar
IMMUNOTHERAPY, 2021, 13 (18) : 1521 - 1533
[22] A Phamacoeconomic Analysis of Personalized Dosing vs Fixed Dosing of Pembrolizumab in Firstline PD-L1-Positive Non-Small Cell Lung Cancer
Goldstein, Daniel A.
Gordon, Noa
Davidescu, Michal
Leshno, Moshe
Steuer, Conor E.
Patel, Nikita
Stemmer, Salomon M.
Zer, Alona
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2017, 109 (11):
[23] Pembrolizumab mono versus Pembrolizumab plus Chemotherapy as first-line Palliative Therapy for PD-L1-high positive Non-small Cell Lung Cancer: a Two-center Study
Olive, E.
Frost, N.
Grohe, C.
PNEUMOLOGIE, 2022, 76 : S93 - S93
[24] Cost-effectiveness analysis of pembrolizumab monotherapy versus chemotherapy for previously untreated advanced non-small cell lung cancer
Aziz, Mohamed Ismail Abdul
Tan, Ling Eng
Tan, Wan Hui Gloria
Toh, Chee-Keong
Loke, Lydia Pui Yee
Pearce, Fiona
Ng, Kwong
JOURNAL OF MEDICAL ECONOMICS, 2020, 23 (09) : 952 - 960
[25] Pembrolizumab monotherapy for PD-L1 ≥50% non-small cell lung cancer, undisputed first choice?
Theelen, Willemijn S. M. E.
Baas, Paul
ANNALS OF TRANSLATIONAL MEDICINE, 2019, 7
[26] Disease Response with the Addition of Platinum-Based Chemotherapy to Pembrolizumab after Progression on Pembrolizumab Monotherapy in PD-L1-Expressing Non-Small Cell Lung Cancer
Garcia, Christine A.
Dacic, Sanja
Villaruz, Liza C.
JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (08) : E135 - E136
[27] Q-TWiST Analysis to Assess Benefit-Risk of Pembrolizumab in Patients with PD-L1-Positive Advanced or Metastatic Non-small Cell Lung Cancer
Huang, Min
Pietanza, M. Catherine
Samkari, Ayman
Pellissier, James
Burke, Thomas
Chandwani, Sheenu
Kong, Fansen
Pickard, A. Simon
PHARMACOECONOMICS, 2019, 37 (01) : 105 - 116
[28] Sintilimab versus Pembrolizumab as Monotherapy or in Combination with Chemotherapy for Treatment Naive Metastatic Non-small Cell Lung Cancer
Liu, S-Y.
Zhou, Q.
Yan, H-H.
Gan, B.
Yang, M-Y.
Deng, J-Y.
Tu, H-Y.
Zhang, X-C.
Su, J.
Yang, J-J.
Wu, Y-L.
JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S381 - S382
[29] Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
Herbst, Roy S.
Baas, Paul
Kim, Dong-Wan
Felip, Enriqueta
Perez-Gracia, Jose L.
Han, Ji-Youn
Molina, Julian
Kim, Joo-Hang
Arvis, Catherine Dubos
Ahn, Myung-Ju
Majem, Margarita
Fidler, Mary J.
de Castro, Gilberto, Jr.
Garrido, Marcelo
Lubiniecki, Gregory M.
Shentu, Yue
Im, Ellie
Dolled-Filhart, Marisa
Garon, Edward B.
LANCET, 2016, 387 (10027): : 1540 - 1550
[30] Pembrolizumab as a monotherapy or in combination with platinum-based chemotherapy in advanced non-small cell lung cancer with PD-L1 tumor proportion score (TPS) ≥50%: real-world data
Dudnik, Elizabeth
Moskovitz, Mor
Rottenberg, Yakir
Lobachov, Anastasiya
Mandelboim, Rinat
Shochat, Tzippy
Urban, Damien
Wollner, Mira
Nechushtan, Hovav
Rotem, Ofer
Zer, Alona
Daher, Sameh
Bar, Jair
ONCOIMMUNOLOGY, 2021, 10 (01):

← 1 2 3 4 5 →